Article

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer setting

2024-03-17

Abstract excerpt

<h4>Background</h4> Immune checkpoint blockade (ICB) has been approved as first-line or second-line therapies for an expanding list of malignancies. T cells recognizing mutation-derived neoantigens are hypothesized to play a major role in tumor elimination. However, the dynamics and characteristics of such neoantigen-reactive T cells (NARTs) in the context of ICB are still limitedly understood. <h4>Methods</h4>...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 49e66106-3417-5876-be15-9199ceb550ab
DOI: 10.1101/2024.03.17.585416

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer settingDOI 10.1101/2024.03.17.585416Read

Cancer neoantigens as potential targets for immunotherapy.Semantic proximity Read

The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives.Semantic proximity Read

New emerging targets in cancer immunotherapy: the role of neoantigensSemantic proximity Read

Neoantigens: The Novel Precision Cancer ImmunotherapySemantic proximity Read

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and ImmunotherapySemantic proximity Read

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapySemantic proximity Read

The Role of Neoantigens in Cancer ImmunotherapySemantic proximity Read

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.Semantic proximity Read

Proteogenomic analysis reveals RNA as an important source for tumor-agnostic neoantigen identification correlating with T-cell infiltrationSemantic proximity Read

Progress in Neoantigen Targeted Cancer ImmunotherapiesSemantic proximity Read

Identification and Targeting of Mutant Peptide Neoantigens in Cancer ImmunotherapySemantic proximity Read

Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.Semantic proximity Read